ObsEva SA (OBSV)
| Market Cap | 187.88M |
| Revenue (ttm) | 19,000 |
| Net Income (ttm) | -81.11M |
| Shares Out | 74.41M |
| EPS (ttm) | -1.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $2.52 |
| Previous Close | $2.59 |
| Change ($) | -0.07 |
| Change (%) | -2.70% |
| Day's Open | 2.55 |
| Day's Range | 2.49 - 2.60 |
| Day's Volume | 1,609,854 |
| 52-Week Range | 1.86 - 5.55 |
Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) i ; agent is being studied in an area of significant unmet need
Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.
-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia –
-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo transfer -
- D ata from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous p reterm labor to be discussed in an oral presentation -
Geneva, Switzerland and Boston, MA – May 31 , 202 1 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive ...
Geneva, Switzerland and Boston, MA – May 25 , 202 1 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive h...
Swiss biopharma ObsEva is on course to introduce an oral treatment for uterine fibroids, which affect 80% of women by menopause. The post OBSV Stock: The Big Clinical Trial News Boosting ObsEva Today ap...
- PRIMROSE 1 76-week results confirm PRIMROSE 2 data showing sustained post- treatment effects and evidence of bone mineral density (BMD) recovery following 52 weeks of treatment -
GENEVA, Switzerland and BOSTON, MA – May 6 , 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive healt...
GENEVA, Switzerland and BOSTON, MA – April 30, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive heal...
- Long-term follow-up study to evaluate bone mineral density in women completing at least 20 weeks of treatment in Phase 3 PRIMROSE 1 or PRIMROSE 2 -
Geneva, Switzerland and Boston, MA – April 22 , 202 1 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive...
-Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21-
Geneva, Switzerland and Boston, MA – March 3, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive heal...
Penny stocks like BLU stock and OBSV stock are gaining traction with retail investors, especially as analyst sentiment heats up. The post Penny Stocks News: Why Little-Known Plays OBSV and BLU Are Climb...
There's an old saying that 'gaps refill'. And that means that these 7 penny stock Bubbles may be about to burst.
Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.
ObsEva (OBSV) stock is soaring higher on Friday as shares see heavy trading despite there not being any noteworthy news today. The post OBSV Stock: 7 Things for ObsEva Investors to Know Before Investing...
In the last round, 36% of recipients saved the money, If you're planning the same with the second payment, here are seven stocks to buy with your stimulus check. The post 7 Stocks to Buy With That Secon...
Geneva, Switzerland and Boston, MA – January 7, 2021 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive he...
Geneva, Switzerland and Boston, MA – January 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's ...
PRIMROSE 1 52-week results confirm the sustained efficacy and continued safety of linzagolix (Yselty®), with a potential best-in-class high-dose option (200 mg with add-back therapy [ABT])
Geneva, Switzerland and Boston, MA – December 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's...
ObsEva (OBSV) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids
Over 50% reduction of pre-term delivery within 48hrs of treatment in singleton pregnancy
Geneva, Switzerland and Boston, MA – November 13, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women'...
Geneva, Switzerland and Boston, MA – November 9, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women'...
Geneva, Switzerland and Boston, MA – 2 November, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women'...
Geneva, Switzerland and Boston, MA – October 22, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproducti...
Geneva, Switzerland and Boston, MA – October 20, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductiv...
ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Loumaye will ...
GENEVA, Switzerland and BOSTON, MA (September 3, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) (“ObsEva” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing nove...
Geneva, Switzerland and Boston, MA – August 7, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductiv...
Primary endpoint successfully met in Phase 3 PRIMROSE 1 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids
Geneva, Switzerland and Boston, MA – July 15, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive ...
PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24
ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that they will present at ESH...
About OBSV
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for pret... [Read more...]
| Industry Biotechnology | IPO Date Jan 26, 2017 |
| CEO Ernest Loumaye | Employees 42 |
| Stock Exchange NASDAQ | Ticker Symbol OBSV |
Analyst Forecasts
According to 6 analysts, the average rating for ObsEva stock is "Buy." The 12-month stock price forecast is 17.67, which is an increase of 601.19% from the latest price.